Company Profile

MANGALAM DRUGS & ORGANICS LTD.

NSE : MANGALAMBSE : 532637ISIN CODE : INE584F01014Industry : Pharmaceuticals & DrugsHouse : Private
BSE55.75-1 (-1.76 % )
PREV CLOSE (Rs.) 56.75
OPEN PRICE (Rs.) 56.70
BID PRICE (QTY) 55.30 (103 )
OFFER PRICE (QTY) 56.25 (5 )
VOLUME 2091
TODAY'S LOW / HIGH (Rs.)55.30 56.70
52 WK LOW / HIGH (Rs.)40.15 177
NSE55.90 -0.15 (-0.27 % )
PREV CLOSE(Rs.) 56.05
OPEN PRICE (Rs.) 55.15
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 10494
TODAY'S LOW / HIGH(Rs.) 55.15 56.15
52 WK LOW / HIGH (Rs.)40 177.5

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 1.17163
Dividend Yield(%)
TTM EPS (Rs.)
P/E Ratio
Book Value (Rs.)
Face Value (Rs.)
MCap (Rs. in Mn)
Price/Earning (TTM)
Price/Sales (TTM)
Price/Book (MRQ)
PAT Margin (%) 6.46
ROCE (%) 25.24
Incorporation Year : 1972

Management Info :

Govardhan M Dhoot - Chairman Govardhan M Dhoot - Managing Director

Registered Office :

Address : ‘3” Floor,237, Rupam Building,P. D. Mello Road,
Mumbai,
Maharashtra-400001

Phone : 91-22-22616200/ 6300/8787

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
16Apr04-16-2019$ Announcement under Regulation 30 (LODR)-Change in Directorate Announcement under Regulati
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that Mr. Ajay Sawhney (DIN: 05132739) has submitted his resignation as an Independent Director of the Company with effect from 16th April, 2019 due to his personal reasons.
In terms of Regulation 30 of SEBI (Listing Obligations and Disc..
01Apr04-01-2019$ Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015 Announcement under Regulati
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has adopted the amended 'Code of Conduct to Regulate, Monitor and Report Trading in Securities' and 'Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information' in Compliance with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. The above code is also being uploaded on the website of the company w.e.f 01st April, 2019. This is for your information and records
Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015,..
15Feb02-15-2019$ Clarification Clarification
With reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded, Mangalam Drugs & Organics Ltd has submitted to BSE a copy of Clarification is enclosed.
With reference to significant movement in price, in order to en..
15Feb02-15-2019$ Clarification Sought on Price Movement Clarification Sought on Pri
The Exchange has sought clarification from Mangalam Drugs & Organics Ltd on February 14, 2019 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.
The Exchange has sought clarification from Mangalam Drugs & Org..
12Feb02-12-2019$ Outcome of Board Meeting Outcome of Board Meeting
In terms of Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that, the meeting of Board of Directors was held today i.e. Monday, 11th February, 2019 at 12.00 P.M at the time scheduled for the meeting at the registered office of the company, where in the following business was inter-alia transacted: 1. Approved the Un-Audited Financial Results for the quarter and nine months ended 31st December, 2018 along with the Limited Review Report on the results pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015; 2. Other Business transacted with permission of chair. The Board Meeting concluded at 3.20 P.M. You are requested to take the same on your records.
In terms of Regulation 30 read with part A of Schedule III of t..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit-44.2198.9
Gross Profit -50.78 293.48
Operating Profit -9.48476.96
Net Sales 485.832793.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Hester Biosciences (BSE)
 1487.50 (2.00%)
M.Cap ( in Cr)
1265.40
Ipca Laboratories (BSE)
 968.95 (2.98%)
M.Cap ( in Cr)
12242.89
Shilpa Medicare (BSE)
 398.70 (5.98%)
M.Cap ( in Cr)
3250.48
Fredun Pharma (BSE)
 473.35 (3.60%)
M.Cap ( in Cr)
188.85
Themis Medicare (BSE)
 297.45 (3.59%)
M.Cap ( in Cr)
273.09
Shareholding Pattern More
NON-INSTITUTION 49.44 %
PROMOTERS 49.27 %
FI/BANKS/INSURANCE 1.29 %
MUTUAL FUNDS/UTI 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS
Scheme NameHold(%)
No Data Found
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested